USA - NASDAQ:CYCN - US23255M2044 - Common Stock
The current stock price of CYCN is 2.46 USD. In the past month the price increased by 5.58%. In the past year, price decreased by -15.17%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.62 | 385.71B | ||
AMGN | AMGEN INC | 12.67 | 148.80B | ||
GILD | GILEAD SCIENCES INC | 14.8 | 142.13B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.29 | 101.15B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 61.07B | ||
REGN | REGENERON PHARMACEUTICALS | 12.27 | 59.35B | ||
ARGX | ARGENX SE - ADR | 81.59 | 46.29B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.67 | 38.56B | ||
INSM | INSMED INC | N/A | 30.85B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.26B | ||
NTRA | NATERA INC | N/A | 23.13B | ||
BIIB | BIOGEN INC | 9.05 | 21.24B |
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
CYCLERION THERAPEUTICS INC
301 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Peter M. Hecht
Employees: 1
Phone: 16176217722
The current stock price of CYCN is 2.46 USD. The price decreased by -3.53% in the last trading session.
The exchange symbol of CYCLERION THERAPEUTICS INC is CYCN and it is listed on the Nasdaq exchange.
CYCN stock is listed on the Nasdaq exchange.
CYCLERION THERAPEUTICS INC (CYCN) has a market capitalization of 8.22M USD. This makes CYCN a Nano Cap stock.
CYCLERION THERAPEUTICS INC (CYCN) currently has 1 employees.
CYCLERION THERAPEUTICS INC (CYCN) has a support level at 2.21 and a resistance level at 2.5. Check the full technical report for a detailed analysis of CYCN support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CYCN does not pay a dividend.
CYCLERION THERAPEUTICS INC (CYCN) will report earnings on 2025-11-12.
CYCLERION THERAPEUTICS INC (CYCN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.74).
The outstanding short interest for CYCLERION THERAPEUTICS INC (CYCN) is 1.17% of its float. Check the ownership tab for more information on the CYCN short interest.
ChartMill assigns a technical rating of 1 / 10 to CYCN. When comparing the yearly performance of all stocks, CYCN is a bad performer in the overall market: 88.97% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to CYCN. While CYCN seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CYCN reported a non-GAAP Earnings per Share(EPS) of -0.74. The EPS increased by 46.04% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -20.77% | ||
ROE | -22.71% | ||
Debt/Equity | 0 |